Mounica Vallurupalli
I am a physician-scientist interested in functional genomics, transcriptional regulation and myeloid disease biology.
Search
Search results
322 results found
Resources
Depmap MetMap Drug Repurposing FireBrowse Cancer Cell Line Encyclopedia FireCloud Cancer Cell Line Factory Genome Data Analysis Center (GDAC) Project Achilles Gene Set Enrichment Analysis (GSEA) Connectivity Map Matrisome Project Clue Connectopedia Molecular Signatures Database (MSigDB) LINCS...
Donaxi Madrigal
Caitlin OSullivan
Ming Chu
Megan Sheeran
An erythroid differentiation signature predicts response to lenalidomide in myelodysplastic syndrome
Ebert, B. L., N. Galili, P. Tamayo, J. Bosco, R. Mak, J. Pretz, S. Tanguturi, et al. 2008. “An Erythroid Differentiation Signature Predicts Response to Lenalidomide in Myelodysplastic Syndrome”. PLoS Med 5: e35.
Cas9 activates the p53 pathway and selects for p53-inactivating mutations
Enache, O. M., V. Rendo, M. Abdusamad, D. Lam, D. Davison, S. Pal, N. Currimjee, et al. 2020. “Cas9 Activates the P53 Pathway and Selects for P53-Inactivating Mutations”. Nat Genet 52: 662-68.
Author Correction: Cas9 activates the p53 pathway and selects for p53-inactivating mutations
Enache, O. M., V. Rendo, M. Abdusamad, D. Lam, D. Davison, S. Pal, N. Currimjee, et al. 2020. “Author Correction: Cas9 Activates the P53 Pathway and Selects for P53-Inactivating Mutations”. Nat Genet 52: 748-49.
Gene expression signatures define novel oncogenic pathways in T cell acute lymphoblastic leukemia
Ferrando, A. A., D. S. Neuberg, J. Staunton, M. L. Loh, C. Huard, S. C. Raimondi, F. G. Behm, et al. 2002. “Gene Expression Signatures Define Novel Oncogenic Pathways in T Cell Acute Lymphoblastic Leukemia”. Cancer Cell 1: 75-87.